Nanoparticle-based vaccines against flaviviruses
Nanoparticle-based vaccines against flaviviruses
批准号:
7647312
负责人:
Michel Ledizet
金额:
$30.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-07-01 至 2012-06-30
关键词:
AdjuvantAluminum HydroxideAnimal ModelAnimalsAntigensAppearanceCessation of lifeDengue VirusDiseaseDoseDrug FormulationsEncapsulatedFlavivirusGlycolatesHumanImmuneImmune responseImmunizationIntranasal AdministrationLifeModelingMonitorMouse StrainsMusNeedlesOligonucleotidesOralPhasePreparationProceduresRecombinant ProteinsRecombinantsRouteSubunit VaccinesT-LymphocyteTechnologyTemperatureTimeToxic effectVaccinatedVaccinationVaccine AntigenVaccinesViralVirusWest Nile virusbasedosageenv Gene Productshuman diseasenanoparticlenanoparticulateneutralizing antibodynonhuman primateparticlepathogenpublic health relevanceresearch studyresponsevaccine developmentvirus envelope
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The objective of this proposal is to develop nanoparticle-based vaccines against West Nile virus. West Nile virus is an emerging human pathogen and a model for other medically important flaviviruses such as dengue virus. We and others have shown that a recombinant subunit vaccine consisting of a truncated form of the flaviviral envelope protein can protect animals from otherwise lethal viral challenges. Here we propose to encapsulate recombinant envelope proteins in biodegradable nanoparticulate cores fabricated from poly(lactic-co-glycolic acid) (PLGA) which have been modified to incorporate immune modulators. Our hypothesis is that this formulation will overcome many weaknesses found in traditional approaches to recombinant subunit vaccine development. First, the formulated antigen is expected to be stable at room temperature for extended periods of time. Second, vaccination can occur with a needle-free procedure (oral or intranasal administration). Finally, our results have shown that immunization with PLGA particles elicits a strong cellular immune response, an essential mechanism to fully eliminate infectious virus. We will synthesize PLGA particles including the envelope protein from West Nile virus. The PLGA particles will include varying concentrations of CpG oligonucleotides as an adjuvant. We will then immunize mice, subcutaneously, orally, and intranasally, with the PLGA preparations. We will vary the number of immunizations and the dose of vaccine administered. The immune response will be characterized in detail. In particular, we will monitor the appearance of virus-neutralizing antibodies as well as virus-specific T cells. We will verify that the immunization is also effective in a distinct strain of mice. Furthermore, we will evaluate the stability of the nanoparticles during storage. Finally, mice immunized with our vaccine against West Nile virus will be challenged with an otherwise lethal dose of live virus. We expect to find that vaccinated animals now survive such a challenge. PUBLIC HEALTH RELEVANCE: Flaviviruses such as West Nile virus and dengue virus cause significant human disease and death. We propose to develop a vaccine against diseases caused by these viruses. The vaccine antigen would be a recombinant protein derived from the viral envelope, and would be encapsulated in nanoparticles. This would allow us to administer the vaccine orally or intranasally.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.4049/jimmunol.1000768
发表时间:
2010-09-01
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Demento SL, Bonafé N, Cui W, Kaech SM, Caplan MJ, Fikrig E, Ledizet M, Fahmy TM]
通讯作者:
Fahmy TM
Vaccination against Zika virus infection using mosquito NeSt1 protein
-
批准号:10194371
-
项目类别:
-
资助金额:$29.39万
-
财政年份:2020
-
负责人:Michel Ledizet
-
依托单位:
Vaccination against Zika virus infection using mosquito NeSt1 protein
-
批准号:10081573
-
项目类别:
-
资助金额:$29.92万
-
财政年份:2020
-
负责人:Michel Ledizet
-
依托单位:
An antigen-detection assay to diagnose Babesia microti infection
-
批准号:10403621
-
项目类别:
-
资助金额:$69.21万
-
财政年份:2018
-
负责人:Michel Ledizet
-
依托单位:
An antigen-detection assay to diagnose Babesia microti infection
-
批准号:10082042
-
项目类别:
-
资助金额:$69.21万
-
财政年份:2018
-
负责人:Michel Ledizet
-
依托单位:
An antigen-detection assay to diagnose Babesia microti infection
-
批准号:10200003
-
项目类别:
-
资助金额:$69.21万
-
财政年份:2018
-
负责人:Michel Ledizet
-
依托单位:
Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens
-
批准号:8876556
-
项目类别:
-
资助金额:$82.57万
-
财政年份:2014
-
负责人:Michel Ledizet
-
依托单位:
A Lyme disease vaccine using newly identified in-vivo expressed antigens
-
批准号:8455815
-
项目类别:
-
资助金额:$29.97万
-
财政年份:2013
-
负责人:Michel Ledizet
-
依托单位:
A Lyme disease vaccine using newly identified in-vivo expressed antigens
-
批准号:8601286
-
项目类别:
-
资助金额:$29.57万
-
财政年份:2013
-
负责人:Michel Ledizet
-
依托单位:
Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens
-
批准号:8782201
-
项目类别:
-
资助金额:$82.94万
-
财政年份:2012
-
负责人:Michel Ledizet
-
依托单位:
Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens
-
批准号:8315248
-
项目类别:
-
资助金额:$29.03万
-
财政年份:2012
-
负责人:Michel Ledizet
-
依托单位:
A serologic assay to measure successful Lyme borreliosis antibiotic therapy
-
批准号:8715103
-
项目类别:
-
资助金额:$88.34万
-
财政年份:2010
-
负责人:Michel Ledizet
-
依托单位:
A serologic assay to measure successful Lyme borreliosis antibiotic therapy
-
批准号:7802551
-
项目类别:
-
资助金额:$27.85万
-
财政年份:2010
-
负责人:Michel Ledizet
-
依托单位:
Nanoparticle-based vaccines against flaviviruses
-
批准号:7537716
-
项目类别:
-
资助金额:$29.14万
-
财政年份:2008
-
负责人:Michel Ledizet
-
依托单位:
Lyme Disease Diagnostics Using In Vivo Expressed Borrelia Burgdorferi Antigens
-
批准号:7404707
-
项目类别:
-
资助金额:$27.58万
-
财政年份:2008
-
负责人:Michel Ledizet
-
依托单位:
Antivirals Targeting Flavivirus Envelope Proteins
-
批准号:7110867
-
项目类别:
-
资助金额:$49.37万
-
财政年份:2006
-
负责人:Michel Ledizet
-
依托单位:
Antivirals Targeting Flavivirus Envelope Proteins
-
批准号:7281246
-
项目类别:
-
资助金额:$50.46万
-
财政年份:2006
-
负责人:Michel Ledizet
-
依托单位:
A Novel Family of Anticoagulants from Ixodes scapularis
-
批准号:6645242
-
项目类别:
-
资助金额:$13.89万
-
财政年份:2003
-
负责人:Michel Ledizet
-
依托单位:
Therapeutic Activity of a Novel Tick Immunosuppressant
-
批准号:6645231
-
项目类别:
-
资助金额:$9.97万
-
财政年份:2003
-
负责人:Michel Ledizet
-
依托单位:
Vaccination Against Ixodes scapularis Tick Bites
-
批准号:6655558
-
项目类别:
-
资助金额:$37.38万
-
财政年份:2001
-
负责人:Michel Ledizet
-
依托单位:
Vaccination Against Ixodes scapularis Tick Bites
-
批准号:6550847
-
项目类别:
-
资助金额:$37.42万
-
财政年份:2001
-
负责人:Michel Ledizet
-
依托单位:
海外基金